The emerging role of cardiac contractility modulation in heart failure treatment

Area of Science:

• Cardiology
• Biomedical Engineering
• Heart Failure Research

Background:

• Heart failure management faces challenges with advanced therapies due to limited availability and high morbidity.
• Cardiac contractility modulation (CCM) presents a non-pharmacological, non-surgical approach to improve cardiac function.
• CCM utilizes nonexcitatory electrical stimulation to enhance ventricular contractility without increasing myocardial oxygen demand.

Purpose of the Study:

• To review the emerging role of Cardiac Contractility Modulation (CCM) in the treatment of heart failure.
• To summarize recent findings on CCM device safety, efficacy, and patient selection.
• To discuss the mechanism of action and potential future applications of CCM.

Main Methods:

• Review of clinical trial data, including FIX-HF-5C and FIX-HF-5C2 studies.
• Analysis of CCM's impact on physiological parameters like peak VO2 and 6-minute walk distance.
• Evaluation of CCM's effect on New York Heart Association (NYHA) functional class.

Main Results:

• The two-lead Optimizer system demonstrated comparable safety and efficacy to prior three-lead systems, simplifying procedures.
• CCM therapy showed consistent improvements in peak VO2, 6-minute walk distance, and NYHA functional class in patients with ejection fraction of 25-45% and NYHA Class III symptoms.
• CCM mitigates heart failure symptoms, reduces hospitalizations, and complements existing guideline-directed therapies.

Conclusions:

• CCM is an emerging therapeutic option for heart failure, enhancing contractility without increasing oxygen demand.
• CCM has demonstrated efficacy in improving exercise capacity and functional status in specific heart failure populations.
• Future research will explore CCM's utility in heart failure with preserved ejection fraction, patients requiring ventricular pacing, and those with atrial arrhythmias.